Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cerevel Therapeutics Holdings (CERE)
NASDAQ:CERE
RESEARCH TOOLSreports
Cerevel Therapeutics Holdings (CERE) Stock Price & Analysis
218 Followers
CERE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.59 - $43.59
Previous Close$42.72
Volume2.63M
Average Volume (3M)1.57M
Market Cap
$7.78B
Enterprise Value$7.31B
Total Cash (Recent Filing)$846.29M
Total Debt (Recent Filing)$368.30M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Jul 30, 2024EPS Estimate
-$0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding182,194,722
10 Day Avg. Volume1,297,298
30 Day Avg. Volume1,573,413
Standard Deviation0.23
R-Squared0.11
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)11.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-19.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-16.34
Forecast
1Y Price Target
$45.00Price Target Upside5.39% Upside
Rating ConsensusHold
Number of Analyst Covering1
Cerevel Therapeutics Holdings News
PremiumCompany Announcements
Cerevel Therapeutics Advances in Merger Amid FTC ReviewBulls Say, Bears Say
Bulls Say
AcquisitionCERE's pending acquisition by ABBV is expected to close, indicating confidence in the deal's completion.
Clinical TrialsCERE announced positive Phase 3 TEMPO-3 study data for tavapadon, a treatment for Parkinson's disease, meeting its primary endpoint and showing a significant increase in 'on' time without troublesome dyskinesia.
Financial PerformanceCERE's share price is currently trading below the acquisition price, suggesting a potential upside if the transaction is completed as planned.
Bears Say
Merger DelayThe FTC's Second Request for additional information on the CERE-ABBV merger extends the waiting period, potentially delaying the deal.
Revenue ContributorTavapadon represents a relatively small revenue contributor to CERE's pipeline efforts.
Stock Price CapThe proposed acquisition of CERE by AbbVie is likely to keep the stock price capped at the December 2023 acquisition offer price, leading to a Neutral rating on CERE.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CERE FAQ
What was Cerevel Therapeutics Holdings’s price range in the past 12 months?
Cerevel Therapeutics Holdings lowest stock price was $19.59 and its highest was $43.59 in the past 12 months.
What is Cerevel Therapeutics Holdings’s market cap?
Currently, no data Available
When is Cerevel Therapeutics Holdings’s upcoming earnings report date?
Cerevel Therapeutics Holdings’s upcoming earnings report date is Jul 30, 2024 which is in 12 days.
How were Cerevel Therapeutics Holdings’s earnings last quarter?
Cerevel Therapeutics Holdings released its earnings results on May 13, 2024. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.658 by -$0.072.
Is Cerevel Therapeutics Holdings overvalued?
According to Wall Street analysts Cerevel Therapeutics Holdings’s price is currently Undervalued.
Does Cerevel Therapeutics Holdings pay dividends?
Cerevel Therapeutics Holdings does not currently pay dividends.
What is Cerevel Therapeutics Holdings’s EPS estimate?
Cerevel Therapeutics Holdings’s EPS estimate is -$0.64.
How many shares outstanding does Cerevel Therapeutics Holdings have?
Cerevel Therapeutics Holdings has 182,194,720 shares outstanding.
What happened to Cerevel Therapeutics Holdings’s price movement after its last earnings report?
Cerevel Therapeutics Holdings reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.658. Following the earnings report the stock price went down -0.308%.
Which hedge fund is a major shareholder of Cerevel Therapeutics Holdings?
Among the largest hedge funds holding Cerevel Therapeutics Holdings’s share is Perceptive Advisors LLC. It holds Cerevel Therapeutics Holdings’s shares valued at 456M.
---
Cerevel Therapeutics Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$45.00 (5.39% Upside)
$45.00 (5.39% Upside)
Blogger Sentiment
Bullish
CERE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.93%
12-Months-Change
Fundamentals
Return on Equity
-92.45%
Trailing 12-Months
Asset Growth
21.17%
Trailing 12-Months
Company Description
Cerevel Therapeutics Holdings
ARYA Sciences Acquisition Corp II is a blank check company.
---
CERE Company Deck
---
CERE Earnings Call
Q3 2023
0:00 / 0:00
---
CERE Stock 12 Month Forecast
Average Price Target
$45.00
▲(5.39% Upside)
Technical Analysis
Bausch Health Companies
―
Crinetics Pharmaceuticals
―
Gritstone Oncology
―
Kala Pharmaceuticals
―
Best Analysts Covering CERE
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+39.20%
reiterated a buy rating 9 months ago
Copying Matthew Harrison's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +39.20% per trade.
---